Search over 3,000 reports

    Ischemic Cardiomyopathy - Pipeline Insights, 2017

    Ischemic Cardiomyopathy - Pipeline Insights, 2017
    Date: Nov, 2017
    Type: Pharmaceutical Industry Report
    Pages: 50
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIPI0145
    DelveInsight's, "Ischemic Cardiomyopathy -Pipeline Insights, 2017", report provides comprehensive insights about pipeline therapies across this indication. The key objective of the report is to establish the understanding for all the pipeline therapies that are undergoing research for the treatment of Ischemic Cardiomyopathy. This report provides information on the therapeutic development for Ischemic Cardiomyopathy, dealing with all the pipeline therapeutics along with the therapies under development by different research institutes. Comparative analysis at various stages covering Phase II, Phase I and Pre-Clinical stages, therapeutic assessment by monotherapy products and molecule type drug information is also covered in this report. The report covers financial information on companies involved in the therapeutic development for this indication. There is a separate section covering all the therapies under different phases of development by various research institutes.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
    Introduction
    Overview
    Pipeline Therapeutics
    Therapeutics under Development by Companies
    Late Stage Products (Filed and Phase III)
    Mid Stage Products (Phase II)
    Early Stage Products (Phase I)
    Discovery and Pre-clinical stage Products
    Unknown stage Products
    TherapeuticAssessment
    Assessment by Monotherapy Products
    Assessment by Combination Therapy Products
    Assessment by Route of Administration
    Assessment by Stage and Route of Administration
    Assessment by Molecule Type
    Assessment by Stage and Molecule Type
    Dormant Products
    Discontinued Products
    Companies Involved in Therapeutics Development
    Appendix
    Consulting Services
    About DelveInsight
    Contact Us
    Disclaimer
    Table 1: Total Products for Ischemic Cardiomyopathy
    Table 2: Mid Stage Products (Phase II)
    Table 3: Early Stage Product (Phase I)
    Table 4: Pre-Clinical Stage Product
    Table 5: Assessment by Monotherapy Products
    Table 6: Assessment by Route of Administration
    Table 7: Assessment by Stage and Route of Administration
    Table 8: Assessment by Molecule Type
    Table 9: Assessment by Stage and Molecule Type
    Table 10: Asklepios proresearch Overvie
    Table 11: Capricor Therapeutics Overview
    Table 12: CoBioRes NV Overview
    Table 13: Vericel Corporation Overview
    Figure 1: Schematic Representation of Plaque formation in Ischemic Cardiomyopathy
    Figure 2: Symptoms of Ischemic Cardiomyopathy
    Figure 3: Total Products for Ischemic Cardiomyopathy
    Figure 4: Mid Stage Products (Phase II)
    Figure 5: Early Stage Product (Phase I)
    Figure 6: Pre-Clinical Stage Product
    Figure 7: Assessment by Monotherapy
    Figure 8: Assessment by Route of Administration
    Figure 9: Assessment by Stage and Route of Administration
    Figure 10: Assessment by Molecule type
    Figure 11: Assessment by Stage and Molecule type
    Ischemic Cardiomyopathy Pipeline Drugs

    Ischemic Cardiomyopathy Pipeline Assessment

    Ischemic Cardiomyopathy Pipeline Analysis

    Ischemic Cardiomyopathy Drugs under Development

    Ischemic Cardiomyopathy Discovery drugs

    Ischemic Cardiomyopathy Preclinical drugs

    Ischemic Cardiomyopathy Phase I drugs

    Ischemic Cardiomyopathy Phase II drugs

    Ischemic Cardiomyopathy Phase III Pipeline Drugs Assessment

    Ischemic Cardiomyopathy Preregistration drugs

    Ischemic Cardiomyopathy Molecules in pipeline

    • Single User License
      (20% Off)
      $1,250.00
      $1000
    • Site License
      (30% Off)
      $2,500.00
      $1750
    • Global License
      (40% Off)
      $4,000.00
      $2400

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap